CardioExchange Archive

November 3rd, 2014

Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective

Larry Husten, PHD

Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) —  and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis. But […]

---

August 21st, 2014

FDA Grants Apixaban Expanded Indication for Venous Thromboembolism

Larry Husten, PHD

The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy. The supplemental new […]

---

April 7th, 2014

Dabigatran Approved for Treatment of DVT and PE

Larry Husten, PHD

Boehringer Ingelheim announced on Monday that the FDA has approved dabigatran (Pradaxa) for the treatment of venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. All three of the new oral anticoagulants — dabigatran, rivaroxaban (Xarelto), […]

---

December 18th, 2013

New Trial Confirms Role for Dabigatran in Venous Thromboembolism

Larry Husten, PHD

A new study helps support a role for  the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE).  The RE-COVER II trial, published online in Circulation, confirms the finding of the earlier and highly similar RE-COVER trial, published in the New England Journal of Medicine in 2009, that dabigatran is as safe and effective as warfarin for […]

---

December 2nd, 2013

Selections from Richard Lehman’s Literature Review: December 2nd

Richard Lehman, BM, BCh, MRCGP

This week’s topic is the risk for first VTE among pregnant women who are hospitalized.

---

September 16th, 2013

Selections from Richard Lehman’s Literature Review: September 16th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the AMPLIFY trial, D2B time and mortality among those undergoing primary PCI, and more.

---

September 1st, 2013

Positive Results for Edoxaban in VTE/PE

Larry Husten, PHD

Findings from the Hokusai-VTE trial of edoxaban

---

June 3rd, 2013

Selections from Richard Lehman’s Literature Review: June 3rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include pacemaker or ICD surgery without interrupting anticoagulation, the diagnostic accuracy of conventional or age-adjusted D-dimer cut-off values in older patients with suspected VTE, and ICD shocks.

---

February 20th, 2013

New Studies Examine Prolonged Anticoagulation for VTE Recurrence

Larry Husten, PHD

Three studies published in the New England Journal of Medicine provide important new information about the risks and benefits of extended prophylaxis using two of the new oral anticoagulants in patients who have had venous thromboembolism (VTE). In the RE-MEDY and the RE-SONATE trials, the role of dabigatran was examined in patients who had completed at least 3 months […]

---

November 4th, 2012

ASPIRE: Aspirin an Attractive Alternative After First VTE

Larry Husten, PHD

It is unclear what the best approach is for the long-term treatment of people who have had a first unprovoked episode of venous thromboembolism (VTE). Although warfarin is effective at preventing a recurrence, it is inconvenient and raises the risk for bleeding. Newer anticoagulants have not been tested or approved for this population. The ASPIRE (Aspirin […]

---